Teleflex Inc (TFX)

Health Services • Health Care

Stock AI

News & Reports

July 29, 2026 Teleflex Inc. Secures FDA Approval for Revolutionary EZPLAZ™ Freeze Dried Plasma Teleflex Incorporated has made a historic advancement by securing FDA approval for EZPLAZ™ Freeze Dried Plasma, the first of its kind. Designed for emergency transfusions, this innovative product addresses critical medical needs and overcomes logistical challenges faced by traditional plasma products.

July 23, 2026 Teleflex Inc. Prepares for Second Quarter 2026 Earnings Call Teleflex Inc. will hold its earnings call on August 6, 2026, at 8:00 a.m. ET, discussing Q2 financial results and operational updates. The call emphasizes the company's commitment to healthcare innovation and improving patient outcomes.

July 21, 2026 Teleflex Secures National Central Venous Access Agreement with Premier, Inc. Teleflex has entered a national group purchasing agreement with Premier, Inc. for central venous access products, effective July 1, 2026. This partnership aims to improve patient safety and operational efficiency in healthcare systems by providing access to Teleflex's innovative vascular access solutions.

July 07, 2026 Teleflex Inc Releases 2025 Global Impact Report: A Commitment to Corporate Social Responsibility Teleflex's 2025 Global Impact Report illustrates the company's dedication to corporate social responsibility, focusing on sustainability, health equity, and environmental improvements. Key highlights include significant reductions in greenhouse gas emissions and a new Global Health Equity Statement aimed at enhancing healthcare access.

June 23, 2026 Teleflex Initiates Enrollment in Groundbreaking BIOMAG™-III Trial Teleflex has initiated the BIOMAG™-III trial to evaluate its innovative Freesolve™ Resorbable Magnesium Scaffold in treating narrowed arteries. This pivotal study aims to compare the new technology with traditional drug-eluting stents and involves nearly 1,900 patients across 120 sites globally. The trial represents a significant advancement in resorbable technologies in cardiology.

June 09, 2026 Teleflex Inc. Reports Promising Four-Year Results for Freesolve™ Resorbable Magnesium Scaffold Teleflex's four-year follow-up data on the Freesolve™ Resorbable Magnesium Scaffold emphasizes its exceptional safety and sustained performance, with no cardiac deaths or major adverse events. The findings support its potential as a leading treatment option in interventional cardiology.

June 01, 2026 Teleflex Inc. Announces $500 Million Private Offering of Senior Notes Teleflex Incorporated has announced a $500 million private offering of senior notes due in 2032, aimed at redeeming existing 2027 notes. This strategic move is designed to optimize their capital structure and reduce interest expenses, positioning the company for future growth.

June 01, 2026 Teleflex Inc. Announces Pricing of $500 Million Senior Notes Offering Teleflex Inc. has priced a private offering of $500 million in senior notes at 5.875%, intended to redeem existing debt and improve financial stability. The offering, targeted at qualified institutions, highlights the company's strategy to enhance cash flow and manage debt effectively.

May 21, 2026 Teleflex Inc. Unveils New Clinical Data at Major Urological Congresses Teleflex recently presented compelling clinical data on the UroLift™ System and Barrigel™ rectal spacer at major urological congresses, highlighting their effectiveness in treating BPH and reducing toxicity in prostate cancer. These innovations underscore Teleflex's commitment to patient-centered healthcare solutions and its strategic focus on critical care markets.

May 07, 2026 Teleflex Inc. Reports Strong First Quarter Results Amid Strategic Transformations Teleflex Incorporated reported a 32.3% revenue increase in Q1 2026, driven by strategic portfolio optimization. The company is set to undergo leadership changes and divestitures to enhance growth and shareholder returns.

April 30, 2026 Teleflex Inc. Appoints New Leadership: Jason Weidman Takes the Helm as CEO Teleflex Incorporated has appointed Jason Weidman as the new CEO, effective June 8, 2026. Weidman, with over 25 years in medical technology, aims to drive growth and innovation as Teleflex transitions into a new era following significant corporate changes.

April 23, 2026 Teleflex Inc Announces Upcoming First Quarter 2026 Earnings Conference Call Teleflex Inc. will host a conference call on May 7, 2026, to discuss its Q1 financial results. Investors can register for participation or access a replay post-call. The event reflects Teleflex's commitment to transparency and innovation in healthcare.

April 09, 2026 Teleflex Announces Governance Updates: A Strategic Shift in Leadership and Operations Teleflex has announced key governance updates, including the nomination of Michael J. Tokich to its Board of Directors and the formation of a new Growth and Operating Committee. These strategic changes aim to enhance operational efficiency and shareholder value, alongside an early commencement of its share repurchase program.

March 27, 2026 Teleflex Inc. Reiterates Commitment to Shareholder Value Amid Irenic Capital Management Demands Teleflex Inc. has reaffirmed its commitment to maximizing shareholder value in response to Irenic Capital Management's demands. The company is engaged in a strategic transformation plan, including divestitures and a focus on operational efficiency, aiming for long-term financial improvement.

February 27, 2026 Teleflex Inc. Reports Strong Revenue Growth Despite Strategic Divestitures and Impairment Charges in 2025 Teleflex Inc. reported a 17.2% revenue increase in 2025, totaling $1.99 billion, despite impairment charges and divestitures. Key growth was driven by the acquisition of BIOTRONIK’s Vascular Intervention business, while strategic transformations aim to enhance financial flexibility and shareholder value.

February 26, 2026 Teleflex Inc. Declares Quarterly Dividend Amid Promising Growth Teleflex Inc. has declared a quarterly dividend of $0.34 per share, emphasizing its strong financial position and commitment to shareholder value. The company continues to invest in innovative medical technologies to enhance patient care and drive growth.

February 26, 2026 Teleflex Inc. Reports Strong 2025 Financial Results and Outlines 2026 Outlook Teleflex Inc. announced robust financial results for 2025 with significant revenue and EPS growth. The company anticipates continued growth in 2026, supported by strategic initiatives and a multi-year restructuring plan.

February 17, 2026 Teleflex Inc. Announces Fourth Quarter 2025 Earnings Conference Call Teleflex Inc. will hold its Q4 2025 earnings conference call on February 26, 2026, at 8:00 a.m. ET. Investors can pre-register and access a replay later in the day.

January 08, 2026 Teleflex Inc. Announces Leadership Transition Amidst Business Restructuring Teleflex has appointed Stuart Randle as Interim CEO amidst a business restructuring, marking a pivotal shift following the sale of key business segments. The company projects revised revenue estimates for 2025 and aims for strategic growth in critical care markets.

December 09, 2025 Teleflex Inc. Announces Strategic Business Divestitures for $2.03 Billion Teleflex Inc. has announced the sale of its Acute Care, Interventional Urology, and OEM businesses for $2.03 billion, aiming to optimize its operations and invest in core growth areas. This strategic move is expected to enhance shareholder value and streamline the company's focus in the medical technology sector.

November 14, 2025 Teleflex Inc. to Showcase Innovations at Jefferies Global Healthcare Conference Teleflex Incorporated will present its latest healthcare innovations at the Jefferies Global Healthcare Conference on November 18, 2025. The live webcast will allow investors to engage with the company's strategic vision and product offerings across key medical sectors.

November 06, 2025 Teleflex Inc. Declares Quarterly Dividend: A Commitment to Shareholder Value Teleflex Inc. has declared a quarterly dividend of $0.34 per share, scheduled for payment on December 15, 2025. This move highlights the company's strong financial health and commitment to shareholder returns while emphasizing its dedication to healthcare innovation.

November 06, 2025 Teleflex Reports Strong Third Quarter Results Amid Strategic Shifts Teleflex's third-quarter results for 2025 show a 19.4% revenue increase, despite challenges in earnings. The company is undergoing strategic restructuring to enhance operational efficiency and shareholder value.

November 06, 2025 Teleflex Inc. Reports 2025 Q3 Financial Results: A Complex Landscape of Growth and Challenges Teleflex Incorporated reported impressive revenue growth of 19.4% in Q3 2025, driven by acquisitions and strategic changes. However, substantial impairment charges and increased operating expenses pose challenges to sustainable growth as the company navigates a complex market landscape.

October 16, 2025 Teleflex Inc. Announces Upcoming Third Quarter Earnings Conference and Vascular Intervention Virtual Event Teleflex has announced its third-quarter earnings conference call on November 6, 2025, followed by a Vascular Intervention virtual meeting on November 14. These events will provide crucial insights into the company's financial health and strategic initiatives in the medical technology sector.

July 31, 2025 Teleflex Inc. Reports Strong Q2 2025 Results Amid Strategic Acquisitions and Market Challenges Teleflex Inc. reported a 4.2% increase in Q2 2025 revenues, reaching $780.8 million. The acquisition of BIOTRONIK's Vascular Intervention business enhances its portfolio, despite facing challenges in some product categories.

May 01, 2025 Teleflex Inc. Reports Q1 2025: Strategic Moves Amidst Revenue Decline Teleflex Inc. reported a 5% decline in Q1 2025 revenue, attributed to decreased sales in existing products. However, strategic acquisitions and restructuring efforts signal a commitment to future growth.

April 30, 2025 Teleflex Inc Faces Fraud Investigation Amid Significant Stock Drop Teleflex Inc. is under investigation for possible securities law violations following a 21.6% stock price drop due to misleading statements about a strategic split and acquisition. Shareholders are encouraged to participate in the inquiry as concerns about transparency grow.

April 29, 2025 Teleflex Inc Faces Securities Class Action Investigation Following Stock Plunge Teleflex Inc. is facing a securities class action investigation after a 21.6% drop in stock price due to allegations of misleading business information. The Rosen Law Firm is urging affected investors to consider their legal options.

April 01, 2025 Teleflex Inc. Achieves FDA Clearance for Innovative AC3 Range™ Intra-Aortic Balloon Pump Teleflex has achieved FDA clearance for its AC3 Range™ Intra-Aortic Balloon Pump, designed to improve patient transport during hemodynamic instability. Enhanced features include a full-size helium tank, dual power options, and improved maneuverability. The device will be available in Q2 2025, reflecting Teleflex's commitment to advancing cardiac care.

March 27, 2025 Teleflex Inc Reports Promising Preliminary Results from Ringer™ Perfusion Balloon Catheter Study Teleflex has reported promising preliminary results from its Ringer™ Perfusion Balloon Catheter study, showing significant efficacy in managing coronary artery perforations during PCI. The study's findings highlight the device's potential to improve patient outcomes despite some serious complications among participants.

March 25, 2025 Teleflex Inc. Unveils Promising Clinical Study Data at EAU Congress Teleflex Inc. presented groundbreaking results from the CLEAR study at the EAU Congress, comparing UroLift™ and Rezūm™ treatments for BPH. Findings reveal superior catheter independence and patient satisfaction with UroLift™, highlighting its potential impact on treatment choices for millions.

February 28, 2025 Teleflex Inc. 2024 Annual Report: A Comprehensive Overview of Financial Performance and Strategic Developments Teleflex Inc.'s 2024 annual report reveals modest revenue growth of 2.4% amid significant operational challenges, including a $240 million goodwill impairment. The report highlights the company's strategic focus on innovation and future acquisitions to enhance its market position.

February 27, 2025 Teleflex Inc. Set to Acquire BIOTRONIK’s Vascular Intervention Business Teleflex Inc. is set to acquire BIOTRONIK's Vascular Intervention business for €760 million, enhancing its interventional cardiology portfolio. This strategic move aims to strengthen its market presence and improve patient outcomes in the growing vascular market.

February 27, 2025 Teleflex Inc. Announces CFO Retirement and Successor Appointment Teleflex Inc. reveals the retirement of CFO Thomas E. Powell, effective April 1, 2025, after over 13 years of service. John R. Deren will succeed him, bringing extensive experience to guide the company's financial strategy. Powell will assist as a consultant to ensure a seamless transition.

February 27, 2025 Teleflex Inc Reports Fourth Quarter and Full Year 2024 Financial Results Teleflex Inc reported mixed financial results for Q4 and full year 2024, with revenue growth but a significant drop in GAAP EPS. The company has outlined strategic moves, including an acquisition and a plan to separate into two entities to enhance operational efficiency.

February 27, 2025 Teleflex Inc. Declares Quarterly Dividend: A Positive Signal for Investors Teleflex Inc. has declared a quarterly cash dividend of $0.34 per share, set to be paid on March 17, 2025. This move signals the company's strong financial health and dedication to returning value to shareholders amidst a competitive market.

February 27, 2025 Teleflex Inc Faces Securities Fraud Investigation Following Dramatic Stock Decline Teleflex Inc's stock plummeted by 20% after announcing a split of its businesses and the resignation of its CFO. Following these developments, a securities fraud investigation has been launched, prompting concerns about corporate governance and investor confidence.

February 27, 2025 Teleflex Inc. Announces Strategic Separation into Two Independent Companies Teleflex Inc. plans to separate into two independent companies, RemainCo and NewCo, to enhance shareholder value and market focus. RemainCo will target high-growth hospital markets, while NewCo will specialize in Urology, Acute Care, and OEM sectors. The separation is expected to complete by mid-2026.

February 19, 2025 SWOT Analysis of Teleflex Inc. in 2025 This SWOT analysis of Teleflex Inc. for 2025 highlights its strengths, such as a robust market presence and innovative products, while addressing weaknesses like regulatory dependencies. It also explores opportunities for growth in emerging markets and the challenges posed by competition and compliance.

February 18, 2025 Teleflex Inc. to Present at Raymond James & Associates 46th Annual Institutional Investors Conference Teleflex Inc. will present at the Raymond James & Associates 46th Annual Institutional Investors Conference on March 4, 2025, highlighting their commitment to healthcare innovation. The presentation will be available via a live webcast, featuring insights into their diverse medical technology portfolio.

February 13, 2025 Teleflex Inc. Prepares to Share Q4 2024 Results in Upcoming Earnings Call Teleflex is set to host its Q4 2024 earnings call on February 27, 2025, at 8:00 a.m. ET. This call will provide insights into the company’s financial performance and operational updates. Participants can join via phone or live audio webcast.

October 31, 2024 Teleflex Inc. Reports Q3 2024 Financial Results: A Mixed Bag Amid Strategic Adjustments Teleflex Inc. announced its Q3 2024 financial results, revealing a 2.4% revenue increase to $764.3 million, despite rising costs from restructuring and pension related charges. The company's strategic adjustments aim to enhance operational efficiency and innovation as it faces a complex market landscape.

August 02, 2024 Teleflex Inc. Reports Mixed Results in Q2 2024 Financial Performance Teleflex Inc. reported a decline in net income for Q2 2024, alongside slight revenue growth. Despite challenges, the company remains optimistic with a robust balance sheet and strategic initiatives aimed at enhancing shareholder value.

May 03, 2024 Teleflex Inc. Reports Mixed Results in Q1 2024: A Closer Look at Financial Performance Teleflex Inc. reported net revenues of $714.1 million for Q1 2024, reflecting a 3.8% increase year-over-year, driven by growth in EMEA and Asia. Despite challenges in the Americas, the company improved its gross margin and net income, but faces ongoing operational costs and restructuring charges.

Teleflex Inc. Prepares to Share Q4 2024 Results in Upcoming Earnings Call

Last updated: February 13, 2025 •

Taurigo

1. Introduction

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced an important event for investors and stakeholders alike. The company will host its fourth quarter earnings conference call on February 27, 2025, at 8:00 a.m. Eastern Time. This call is a key opportunity for the company to discuss its financial performance for Q4 2024 and provide an operational update.

2. Conference Call Details

Participation Information

The conference call can be accessed through a pre-registration link provided by Teleflex, enabling participants to receive dial-in information directly. For those unable to join via phone, the call will also be available as a live audio webcast on Teleflex’s official website, teleflex.com.

Replay Availability

For stakeholders who wish to revisit the discussions, an audio replay will be made available starting at 11:00 a.m. Eastern Time on the same day, February 27, 2025. The replay can be accessed on the Teleflex website or via telephone at specific numbers: 1 800 770 2030 for U.S. and Canada callers, and 1 609 800 9909 for international participants. The conference ID to be used for accessing the replay is 69028.

3. About Teleflex Incorporated

Teleflex is on a mission to enhance health and improve the quality of life for patients globally. The company’s commitment to innovation is reflected in its diverse portfolio, which spans several critical therapy areas including:

Anesthesia

Emergency Medicine

Interventional Cardiology

Radiology

Surgical

Vascular Access

Urology

Teleflex prides itself on being a trusted partner in healthcare, with a focus on purpose-driven innovation and world-class products. Their extensive range of trusted brands—including Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™, and Weck™—illustrates their commitment to quality and reliability in medical technologies.

4. Conclusion

As Teleflex prepares for its fourth quarter earnings call, stakeholders are encouraged to participate and gain insights into the company’s financial performance and future outlook. With a robust portfolio of medical technologies and a clear vision to empower the future of healthcare, Teleflex continues to position itself as a leader in the medical technology space. For more information about the upcoming call and Teleflex’s offerings, visit teleflex.com.

Contacts:

For further inquiries, please reach out to:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

Phone: 610-948-2836

Email: investors.teleflex.com

This earnings call represents not just a reporting obligation but a pivotal moment for Teleflex to engage with its investors and share its vision for the future of healthcare.

Original press release

You may also be interested in: